Small Interfering RNA Strategies to Overcome Drug Resistance in Cancer: Pathway Targeting and Translational Advances

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Therapeutic resistance is a major hurdle in cancer treatment, limiting the effectiveness of chemotherapy and targeted agents.
• Resistance mechanisms are diverse and complex, often involving targets like transcription factors inaccessible to conventional drugs.
• Current strategies like dose escalation face toxicity and tumor evolution challenges.

Purpose of the Study:

• To review the molecular mechanisms of siRNA-mediated gene silencing.
• To evaluate siRNA-based strategies for overcoming cancer drug resistance.
• To highlight advances in siRNA chemical modification and delivery for cancer therapy.

Main Methods:

• Review of preclinical and translational studies on siRNA in cancer resistance.
• Analysis of siRNA targeting of resistance-associated messenger RNAs.
• Examination of clinical trials validating siRNA approaches in oncology.

Main Results:

• siRNA therapeutics can degrade resistance-associated messenger RNAs, targeting both druggable and undruggable cancer drivers.
• Advances in siRNA technology improve stability, specificity, and in vivo gene silencing.
• Studies show siRNA can reverse multidrug resistance, restore apoptosis sensitivity, and suppress oncogenic signaling.

Conclusions:

• siRNA represents a promising therapeutic strategy to overcome diverse cancer drug resistance mechanisms.
• Pathway-centric targeting by siRNAs addresses limitations of conventional cancer treatments.
• Emerging clinical trials support the translational potential of siRNA-based cancer therapies.